In this episode of Hormone Insight, we examine a 2024 post hoc analysis published in Diabetes Care.

Exploring Semaglutide: Dual Action Therapy for Obesity and Heart Failure

In this episode of Hormone Insights, we delve into a 2024 study from the New England Journal of Medicine that examines the effects of semaglutide in obese patients with heart failure, preserved ejection fraction, and type 2 diabetes.

For full paper, click here

Visit HormoneInsight

In this episode of Hormone Insight, we delve into a major study published in The Lancet Diabetes and Endocrinology that compared the effects of semaglutide and canagliflozin as add-ons to metformin in diabetes treatment.

For more: Semaglutide vs Canagliflozin for Type 2 Diabetes

To read the original paper

In patients with heart failure with preserved ejection fraction (HFpEF) and obesity, tirzepatide significantly reduced the composite risk of cardiovascular death or worsening heart failure and improved health status compared to placebo, though it was associated with higher gastrointestinal side effects.

For summary, click here.

Packer M, Zile MR, Kramer CM, et al. (2024). “Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.” New England Journal of Medicine. DOI: 10.1056/NEJMoa2410027

In patients with type 2 diabetes, intensive blood-pressure control (targeting systolic BP <120 mm Hg) significantly reduced cardiovascular events compared to standard treatment (systolic BP <140 mm Hg), though it was associated with increased risks of symptomatic hypotension and hyperkalemia.

Bi, Y., Li, M., Liu, Y., et al. (2024). “Intensive Blood-Pressure Control in Patients with Type 2 Diabetes.” New England Journal of Medicine. doi:10.1056/NEJMoa2412006

For summary - click here.

This episode explores the potential of semaglutide, a once-weekly GLP-1 analog, in managing type 2 diabetes. We examines a groundbreaking study published in Diabetes Care which found that semaglutide effectively reduces HbA1c levels and promotes weight loss in patients. The episode breaks down the study's findings, highlighting the dose-dependent effects of semaglutide and strategies for managing potential side effects. Tune in for insights into this promising new treatment option.

Nauck, M.A., Petrie, J.R., Sesti, G. et al., 2016. A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes. Diabetes Care, 39(2), pp.231–241.

https://doi.org/10.2337/dc15-0165